Brokerages Set Intrexon Corp. (XON) Price Target at $43.78
Intrexon Corp. (NYSE:XON) has been given a consensus recommendation of “Buy” by the nine brokerages that are currently covering the company. Four research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $43.78.
XON has been the topic of a number of analyst reports. Vetr cut Intrexon Corp. from a “sell” rating to a “strong sell” rating and set a $22.26 price target on the stock. in a research report on Wednesday, July 27th. Zacks Investment Research cut Intrexon Corp. from a “buy” rating to a “hold” rating in a research report on Friday, August 12th. Griffin Securities reiterated a “buy” rating and issued a $55.00 price target on shares of Intrexon Corp. in a research report on Tuesday, August 16th. JMP Securities reiterated a “buy” rating on shares of Intrexon Corp. in a research report on Thursday, November 10th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Intrexon Corp. in a research report on Friday, November 11th.
In other news, SVP Nir Nimrodi purchased 4,000 shares of the business’s stock in a transaction dated Monday, August 29th. The shares were acquired at an average price of $26.12 per share, with a total value of $104,480.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 55.10% of the company’s stock.
Several institutional investors have recently modified their holdings of the stock. Aperio Group LLC purchased a new position in shares of Intrexon Corp. during the first quarter valued at about $299,000. TIAA CREF Investment Management LLC raised its position in shares of Intrexon Corp. by 2.3% in the first quarter. TIAA CREF Investment Management LLC now owns 141,930 shares of the company’s stock valued at $4,810,000 after buying an additional 3,189 shares during the period. Teachers Advisors Inc. raised its position in shares of Intrexon Corp. by 8.9% in the first quarter. Teachers Advisors Inc. now owns 37,984 shares of the company’s stock valued at $1,287,000 after buying an additional 3,104 shares during the period. BlackRock Inc. raised its position in shares of Intrexon Corp. by 321.0% in the first quarter. BlackRock Inc. now owns 5,780 shares of the company’s stock valued at $195,000 after buying an additional 4,407 shares during the period. Finally, BlackRock Group LTD raised its position in shares of Intrexon Corp. by 9.1% in the first quarter. BlackRock Group LTD now owns 33,713 shares of the company’s stock valued at $1,143,000 after buying an additional 2,816 shares during the period. 84.94% of the stock is currently owned by institutional investors and hedge funds.
Shares of Intrexon Corp. (NYSE:XON) opened at 31.19 on Monday. The company’s market capitalization is $3.70 billion. The firm has a 50-day moving average of $27.27 and a 200 day moving average of $26.79. Intrexon Corp. has a 12 month low of $18.52 and a 12 month high of $40.24.
Intrexon Corp. (NYSE:XON) last released its quarterly earnings data on Wednesday, November 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by $0.03. Intrexon Corp. had a negative net margin of 93.97% and a negative return on equity of 18.46%. The firm had revenue of $48.99 million for the quarter, compared to the consensus estimate of $51.70 million. During the same quarter in the prior year, the firm posted ($0.34) earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, equities research analysts expect that Intrexon Corp. will post ($1.43) earnings per share for the current fiscal year.
About Intrexon Corp.
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
Receive News & Stock Ratings for Intrexon Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp. and related stocks with our FREE daily email newsletter.